Articles

The potential role of the combination of pertuzumab, hormone therapy, plus an aromatase inhibitor as first-line treatment for HER2-positive metastatic or locally advanced breast cancer is further supported by the final analysis of the PERTAIN trial. Read More ›

Among patients with HER2-positive metastatic breast cancer, the healthcare resource utilization of brain metastases is significantly higher when compared with patients without brain metastases, underscoring the critical need for effective systemic therapies that improve outcomes and decrease the burden of disease. Read More ›

Elderly patients with HER2-positive advanced breast cancer demonstrated shorter chemotherapy durations, poorer overall survival, and increased rates of adverse events, emphasizing the need for prospective studies to improve outcomes. Read More ›

This real-world study of community-based oncology clinics demonstrates that patients receive variable treatment patterns in later line settings, and there is no clear management strategy being utilized. With recently approved targeted therapies for HER2-positive metastatic breast cancer, improvements in patient outcomes are slowly being seen. Read More ›

A phase 2 trial of Enhertu (trastuzumab deruxtecan) in patients with HER2-positive metastatic breast cancer show high rates of positive results in patients who have been heavily pretreated. These results are preliminary and encouraging. Read More ›

Identified subpopulations of patients showed the largest absolute advances in 6-year invasive disease-free survival for pertuzumab compared with placebo. Read More ›

Breast cancer and its treatment impacts sexual health, which is an important topic for patients and clinicians to be able to address throughout the treatment process. Read More ›

Treatment-related amenorrhea with a standard combination chemotherapy regimen occurred at a rate that was nearly double that observed with trastuzumab emtansine plus pertuzumab, implying that gonadal function may be preserved through an antibody–drug conjugate regimen. Read More ›

The DESTINY-Breast05 trial will help researchers understand the potential benefit of Enhertu (trastuzumab deruxtecan), a powerful potential treatment of patients with breast cancer with residual invasive disease after receiving chemotherapy. Read More ›

An increase in neoadjuvant therapy use has paralleled shifts in the standard anti-HER2 therapies; however, neoadjuvant patients are primarily treated with dual HER2 blockade and chemotherapy, with a taxane-based regimen preference. Read More ›